2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the US Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials intended to support marketing applications. The writing committee recognizes that these definitions may be used in other types of clinical trials and clinical care processes where appropriate. Use of these definitions at the FDA has enhanced the ability to aggregate data within and across medical product development programs, conduct meta-analyses to evaluate cardiovascular safety, integrate data from multiple trials, and compare effectiveness of drugs and devices. Further study is needed to determine whether prospective data collection using these common definitions improves the design, conduct, and interpretability of the results of clinical trials.

James E. Tcheng | Christopher J. White | Norman L. Stockbridge | Akshay S. Desai | Steven E. Nissen | Steven R. Steinhubl | David A. Morrow | Kenneth W. Mahaffey | Laura Mauri | Paul Burton | Robert J. Temple | Scott D. Solomon | Christopher M. O’Connor | Michael R. Jaff | Billy Dunn | Roxana Mehran | John J.V. McMurray | M. Landray | S. Solomon | M. Pfeffer | C. O'connor | A. Desai | S. Steinhubl | J. McMurray | B. Dunn | M. Domanski | K. Mahaffey | N. Stockbridge | J. Marler | B. Chaitman | D. Morrow | A. Farb | L. Mauri | A. Lincoff | R. Mehran | S. Nissen | A. Lansky | R. Temple | J. Tcheng | M. Jaff | C. Gibson | D. Cutlip | S. Wiviott | K. Rosenfield | C. White | H. M. Hung | C. Sila | Bernard R. Chaitman | Andrew Farb | Stephen D. Wiviott | Marc A. Pfeffer | C. Michael Gibson | J. Teerlink | K. Hicks | S. Targum | Hylton V. Joffe | E. Lewis | S. Brooks | P. Burton | M. T. Hai | Eldrin F. Lewis | John R. Marler | Alexandra J. Lansky | John R. Teerlink | Martin J. Landray | Michael J. Domanski | Karen A. Hicks | Shari L. Targum | Cathy A. Sila | Mary T. Thanh Hai | Donald E. Cutlip | A. Michael Lincoff | Steven S. Brooks | Kenneth Rosenfield | H.M. James Hung | A. Lincoff | C. White | C. M. Gibson | Michael R. Jaff | Christopher J. White | Marc A. Pfeffer | Scott D Solomon | Akshay S. Desai | David Morrow | Alexandra J. Lansky | Karen A. Hicks | Steven E. Nissen | John R. Marler | Cathy Sila | Mary T. Thanh Hai | C. Michael Gibson | Michael J. Domanski | J. McMurray | Christopher M. O’Connor | H. Hung | Norman L. Stockbridge | Robert J. Temple | David A Morrow | Scott D. Solomon

[1]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.

[2]  Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. , 1979, Circulation.

[3]  J. Karnegis,et al.  Development and evolution of electrocardiographic Minnesota Q-QS codes in patients with acute myocardial infarction. , 1985, American heart journal.

[4]  J. Slattery,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1989, Stroke.

[5]  Robert A. Zimmerman,et al.  Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. , 1990, Stroke.

[6]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[7]  R. Califf,et al.  Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study , 2001, Current controlled trials in cardiovascular medicine.

[8]  J. Mohr,et al.  Transient ischemic attack--proposal for a new definition. , 2002, The New England journal of medicine.

[9]  P. Wolf,et al.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.

[10]  Karl Swedberg,et al.  Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.

[11]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[12]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[13]  C. Granger,et al.  Do we need to adjudicate major clinical events? , 2008, Clinical trials.

[14]  Regina M. Hardison,et al.  The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease: Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction , 2009, Circulation.

[15]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[16]  M. Laakso,et al.  Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. , 2010, European heart journal.

[17]  P. Toth Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study , 2010 .

[18]  S. Blankenberg,et al.  Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. , 2011, JAMA.

[19]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[20]  Mary G. George,et al.  An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[21]  A. Sinha Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). , 2013 .

[22]  E. Braunwald,et al.  Unstable Angina: Is It Time for a Requiem? , 2013, Circulation.

[23]  R. Rosenfeld Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[24]  S. Solomon,et al.  Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT‐CRT , 2014, European journal of heart failure.

[25]  Robert H Christenson,et al.  Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. , 2014, Journal of the American College of Cardiology.

[26]  M. Mack,et al.  Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: An expert consensus document from the society for cardiovascular angiography and interventions (SCAI) , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[27]  B. Lindahl,et al.  Implications of Introducing High-Sensitivity Cardiac Troponin T Into Clinical Practice: Data From the SWEDEHEART Registry. , 2015, Journal of the American College of Cardiology.

[28]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.

[29]  Mark D. Huffman,et al.  Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association , 2016, Circulation.

[30]  S. Solomon,et al.  Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). , 2016, Circulation.

[31]  Jeffrey N. Browndyke,et al.  Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative , 2018, European heart journal.